Social Behavior – Page 12

Flagship’s Winning Streak Continues with Singapore R&D Partnership

8 months ago talkbio0Tagged Collaboration, Flagship, innovation, R&D, Singapore

Flagship, R&D collaboration, Singapore, biotech, innovation

CMS Prepares for Second Round of Medicare Drug Price Negotiation Program

8 months ago talkbio0Tagged drug price, Economic Inflation, Fair Language Proficiency, Mediation, Medicare, MFPs, Myasthenic Syndromes, Congenital, Negotiation Program, Part D

Medicare Drug Price Negotiation Program, CMS, drug price negotiations, Inflation Reduction Act, Part D drugs, maximum fair prices (MFPs)

Senators Wyden and Brown Call for FTC Investigation into PBM “Co-Manufacturing” Practices

8 months ago talkbio0Tagged Benefit, Co-Manufacturing, competition, Drug Costs, Evaluation, Healthcare Industry, manager, Pharmaceutical Services, Pharmacy Benefit Manager, United States Federal Trade Commission

PBM reforms, FTC investigation, co-manufacturing, pharmacy benefit managers, drug costs, competition, healthcare industry

IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce

8 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Changing, Immunoglobulin M, imvotamab, Leadership, strategic pivot, T cell-engaging IgM antibodies

IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644

Senators Wyden and Brown Urge FTC to Expand Investigation into PBMs’ Anti-Competitive Practices

9 months ago talkbio0Tagged Agreement, Anti-Competitive, Benefit Managers, Co-Manufacturing, Evaluation, Health Care Reform, PBMs, Pharmaceutical Services, Prices, United States Federal Trade Commission

Pharmacy Benefit Managers (PBMs), Anti-Competitive Practices, FTC Investigation, Co-Manufacturing Agreements, Drug Prices, Healthcare Reform

Metsera and Amneal Collaborate on Next-Generation Obesity Medicines, with Leadership Transition at Metsera

9 months ago talkbio0Tagged Amneal, Leadership, Manufacture, Metsera, Obesity, Partnership, strategic collaboration, Transition Mutation

Metsera, Amneal, Obesity Drugs, Strategic Collaboration, Manufacturing Partnership, Leadership Transition

Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025

9 months ago talkbio0Tagged Diabetes, Economic Inflation, Mediation, Medicare, Nordisk, Ozempic, Prices

Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act

AI Guidance for Investors: Navigating the Future with Strategic Approaches and Regulatory Insights

9 months ago talkbio0Tagged Adoption, Advice, Artificial Intelligence, Computer Security, governance, Health care facility, investors, Mapping Strategies, Regulatory Impact, Risk, Strategic AI

AI Guidance for Investors, Strategic AI Adoption, Regulatory Impact on AI, Cybersecurity Risks in AI, AI Mapping Strategies, Data Governance in AI, Future of AI in Healthcare

Vanda Pharmaceuticals Receives FDA Rejection for Gastroparesis Treatment, Criticizes Agency’s Decision

9 months ago talkbio0Tagged conclusory, Gastroparesis, refusal, Rejection (Psychology), Tradipitant, United States Food and Drug Administration, Vanda Pharmaceuticals

Vanda Pharmaceuticals, FDA rejection, gastroparesis treatment, tradipitant, conclusory refusal

Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease

9 months ago talkbio0Tagged Antibodies, biopharmaceutical development, Clinical Trials, Phase 3, Success, Thrive, Thyroid associated opthalmopathies, Veligrotug, VRDN-001

Veligrotug (VRDN-001), Thyroid Eye Disease (TED), Phase 3 THRIVE Clinical Trial, Anti-IGF-1R Antibody, Clinical Trial Success, Biopharmaceutical Development